Noetik Presents Multimodal Discovery Engines at AACR 2025: OCTO-virtual cell and Perturb-map

SAN FRANCISCO — April 28, 2025 — Noetik, an AI-native biotechnology company pioneering the use of foundation models and high-throughput spatial biology to accelerate cancer drug discovery, announced today the presentation of two research posters at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, Illinois. The presentations showcase advances in Noetik’s AI-enabled discovery platforms, including OCTO-virtual cell, a foundation model of cell and tissue biology, and Perturb-map, a high-throughput in vivo system for therapeutic target identification and immunophenotype modeling.
‍

The OCTO-virtual cell poster demonstrates how large-scale, multimodal machine learning models trained on diverse spatial datasets can capture the complexity of tumor-immune interactions, enabling improved patient stratification and target discovery. “OCTO-virtual cell is a step function improvement in how we interpret the cellular and spatial architecture of human tumors,” said Yubin Xie, Ph.D., Senior Machine Learning Scientist at Noetik and presenter. “By training on vast amounts of multimodal data, it learns rich, generalizable representations of biology - helping us identify distinct patient subpopulations and uncover new, spatially informed drug targets that were previously inaccessible."
‍

Perturb-map highlights Noetik’s platform that models human immunotypes in vivo at scale, bridging critical gaps between traditional mouse models and real-world patient biology.  “This initial dataset - mapping the impact of >600 perturbations on tumor immunotypes and response to immune checkpoint blockade - demonstrates that we can generate mouse models at scale that better capture the heterogeneity of human disease” said Maxime Dhainaut, Ph.D., Director of Spatial Functional Genomics at Noetik and presenter. “We can now test pharmacologic and therapeutic hypotheses in these models simultaneously, which helps to identify which patient population would benefit the most from any given drug.”
‍

The abstracts will be published in the Proceedings of the American Association for Cancer Research. AACR, the world’s oldest and largest professional association dedicated to advancing cancer research, is holding its 2025 Annual Meeting from April 25–30 in Chicago, Illinois.